1	6 patient must have be off chemotherapy for 2 week prior to entering this study and recover from the toxic effect of that therapy unless there be evidence of rapidly progressive disease use of hydroxyurea for patient with rapidly proliferative disease be allow for the first two week on therapy imatinib|imatinib[295,303]|||||||two week[275,283]||C0935989|282388|282388|imatinib
1	6 patient must have be off chemotherapy for 2 week prior to entering this study and recover from the toxic effect of that therapy unless there be evidence of rapidly progressive disease use of hydroxyurea for patient with rapidly proliferative disease be allow for the first two week on therapy imatinib|hydroxyurea[193,204]|||||||2 week[44,50]||C0020402|5552|5552|hydroxycarbamide
2	mesylate gleevec and anagrelide must also be stop 2 week prior to entering this study|gleevec[313,320]||||||||||282386|282388|imatinib
2	mesylate gleevec and anagrelide must also be stop 2 week prior to entering this study|mesylate[304,312]||||||||||6820|6820|mesylate
2	mesylate gleevec and anagrelide must also be stop 2 week prior to entering this study|anagrelide[325,335]|||||||2 week[354,360]||C0051809|596724|596724|anagrelide
